Summary
Infections with highly resistant grampositive bacteria are a major threat to the patients with underlying malignant diseases and due to more aggressive treatment strategies the incidence of these infections increased over the past years. For many years, glycopeptides such as vancomycin, have been the standard treatment for methicillin-resistant S. aureus (MRSA) and ampicillin-resistant enterococci. However, the clinical use of vancomycin may be limited by the adverse effects like poor tissue penetration and the emergence of vancomycin-resistant strains such as vancomycin-resistant enterococci and staphylococci. Thus, in recent years, new antimicrobial agents have been introduced into clinical praxis or are under investigation. This review summarizes current clinical data on novel therapeutics such as linezolid, tigecycline and daptomycin as well as investigational new drugs. Linezolid, an oxazolidinone derivative, has proven clinical activity only against infections with grampositive bacteria including vancomycin-resistant rods. Tigecycline is a tetracycline derivative with a very broad antimicrobial spectrum including multiresistant grampositive strains. Daptomycin, belonging to a new class of cyclic lipopeptide antibiotics, is approved for the treatment of skin and skin-structure infections, bactermia and endocarditis with grampositive bacteria. However, only limited data exist on the clinical use of tigecycline and daptomycin in oncological patients. In the near future, novel cephalosporins and carbapenems with activity against MRSA as well as new semisynthetic glycopeptides will extend our therapeutic possibilities in the treatment of infections by multiresistant grampositive bacteria.
Similar content being viewed by others
References
Phair JP, Riesing KS, Metzger E. Bacteremic infection and malnutrition in patients with solid tumors: investigation of host defense mechanisms. Cancer, 45(10): 2702–2706, 1980
Koll BS, Brown AE. The changing epidemiology of infections at cancer hospitals. Clin Infect Dis, 17(Suppl 2): S322–S328, 1993
Morris PG, et al. Emergence of MRSA in positive blood cultures from patients with febrile neutropenia-a cause for concern. Support Care Cancer, 2008 February 15 [Epub ahead of print]; DOI: 10.1007/s00520-007-0398-5
Cosgrove SE, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis, 36(1): 53–59, 2003
EARSS, European Antimicrobial Resistance Surveillance System. http://www.rivm.nl/earss/
Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis, 7(2): 178–182, 2001
Moellering RC, Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med, 138(2): 135–142, 2003
Weigelt J, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother, 49(6): 2260–2266, 2005
Rubinstein E, et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis, 32(3): 402–412, 2001
Wunderink RG, et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest, 124(5): 1789–1797, 2003
Smith PF, et al. Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia. Ann Oncol, 14(5): 795–801, 2003
Jaksic B, et al. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis, 42(5): 597–607, 2006
Youssef S, et al. The role of vitamin B6 in the prevention of haematological toxic effects of linezolid in patients with cancer. J Antimicrob Chemother, 61(2): 421–424, 2008
Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis, 43(2): 180–187, 2006
Projan SJ. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy, 20(9 Pt 2): 219S–223S; discussion 224S–228S, 2000
Petersen PJ, et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother, 43(4): 738–744, 1999
Ellis-Grosse EJ, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis, 41(Suppl 5): S341–S353, 2005
Breedt J, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother, 49(11): 4658–4666, 2005
Babinchak T, et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis, 41(Suppl 5): S354–S367, 2005
Steenbergen JN, et al. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother, 55(3): 283–288, 2005
Arbeit RD, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis, 38(12): 1673–1681, 2004
Fowler VG Jr, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med, 355(7): 653–665, 2006
Silverman JA, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis, 191(12): 2149–2152, 2005
Poutsiaka DD, et al. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect, 54(6): 567–571, 2007
Noel GJ, et al. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis, 46(5): 647–655, 2008
Noel GJ, et al. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother, 52(1): 37–44, 2008
Talbot GH, et al. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother, 51(10): 3612–3616, 2007
Koga T, et al. In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem. Antimicrob Agents Chemother, 49(8): 3239–3250, 2005
Kihara R, et al. Potency of SMP-601, a Novel Carbapenem, in Hematogenous Murine Bronchopneumonia Caused by Methicillin-Resistant and Vancomycin-Intermediate Staphylococcus aureus. Antimicrob Agents Chemother, 52(6): 2163–2168, 2008
Raad I, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis, 40(3): 374–380, 2005
Seltzer E, et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis, 37(10): 1298–1303, 2003
Jauregui LE, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis, 41(10): 1407–1415, 2005
Stryjewski ME, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis, 46(11): 1683–1693, 2008
Micek ST, Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis, 45(Suppl 3): S184–S190, 2007
Peppard WJ, Schuenke CD. Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections. Curr Opin Investig Drugs, 9(2): 210–225, 2008
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fritsche, G., Weiss, G. Therapeutic options for the treatment of infections with multiresistant grampositive bacteria in oncological patients. memo 1, 177–180 (2008). https://doi.org/10.1007/s12254-008-0057-7
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s12254-008-0057-7